ATE474857T1 - Antikörper gegen ein epitop auf agr2, assays und hybridome - Google Patents

Antikörper gegen ein epitop auf agr2, assays und hybridome

Info

Publication number
ATE474857T1
ATE474857T1 AT07789322T AT07789322T ATE474857T1 AT E474857 T1 ATE474857 T1 AT E474857T1 AT 07789322 T AT07789322 T AT 07789322T AT 07789322 T AT07789322 T AT 07789322T AT E474857 T1 ATE474857 T1 AT E474857T1
Authority
AT
Austria
Prior art keywords
antibodies
agr2
epitope
hybridome
assay
Prior art date
Application number
AT07789322T
Other languages
English (en)
Inventor
Roger Barraclough
Dong Barraclough
Philip Rudland
Original Assignee
Univ Liverpool
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liverpool filed Critical Univ Liverpool
Application granted granted Critical
Publication of ATE474857T1 publication Critical patent/ATE474857T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07789322T 2006-08-26 2007-08-28 Antikörper gegen ein epitop auf agr2, assays und hybridome ATE474857T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0616929.6A GB0616929D0 (en) 2006-08-26 2006-08-26 Antibodies, assays and hybridomas
PCT/GB2007/003235 WO2008025964A2 (en) 2006-08-26 2007-08-28 Antibodies to an epitope of agr2. assays and hybridomas

Publications (1)

Publication Number Publication Date
ATE474857T1 true ATE474857T1 (de) 2010-08-15

Family

ID=37102874

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07789322T ATE474857T1 (de) 2006-08-26 2007-08-28 Antikörper gegen ein epitop auf agr2, assays und hybridome

Country Status (11)

Country Link
US (1) US8329875B2 (de)
EP (1) EP2054443B1 (de)
AT (1) ATE474857T1 (de)
AU (1) AU2007291077B2 (de)
CA (1) CA2661803A1 (de)
DE (1) DE602007007958D1 (de)
DK (1) DK2054443T3 (de)
ES (1) ES2351801T3 (de)
GB (1) GB0616929D0 (de)
PT (1) PT2054443E (de)
WO (1) WO2008025964A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100983386B1 (ko) * 2008-09-12 2010-09-20 성균관대학교산학협력단 난소암 진단을 위한 ａｇｒ-2의 신규한 용도
CN101519649B (zh) * 2009-01-22 2010-11-03 上海交通大学 杂交瘤细胞株及其制备方法
WO2012116357A2 (en) 2011-02-25 2012-08-30 The Board Of Trustees Of The Leland Use of agr3 for treating cancer
CN102268089A (zh) * 2011-07-05 2011-12-07 上海交通大学 Agr2阻断抗体及其用途
WO2013040358A2 (en) * 2011-09-14 2013-03-21 University Of Washington Through Its Center For Commercialization Assays and compositions for detection of agr2
JP2017534251A (ja) * 2014-09-09 2017-11-24 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ａｇｒ２およびその受容体ｃ４．４ａに対する遮断モノクローナル抗体
CN109576229A (zh) * 2018-12-13 2019-04-05 华中科技大学同济医学院附属协和医院 一种分泌抗agr2的单克隆抗体杂交瘤细胞株及其应用
CN113336853B (zh) * 2020-11-04 2022-06-14 华中科技大学同济医学院附属协和医院 针对agr3蛋白的单克隆抗体、制备方法及其应用
EP4274617A4 (de) * 2021-01-05 2025-04-02 Musc Foundation for Research Development Ein bispezifischer agr2xcd3-engager zur behandlung von krebs
WO2022150754A2 (en) * 2021-01-11 2022-07-14 University Of Florida Research Foundation, Incorporated Anticancer compounds and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319089A1 (en) * 1998-04-09 1999-10-21 Genset S.A. 5' ests and encoded human proteins
GB0004576D0 (en) * 2000-02-25 2000-04-19 Oxford Glycosciences Uk Ltd Proteins
US20040141974A1 (en) * 2000-02-25 2004-07-22 Boyd Robert Simon Diagnostic and therapeutic methods
AU2003209459A1 (en) * 2002-03-06 2003-09-16 Hybrigenics Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
GB0222787D0 (en) 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
WO2004044178A2 (en) * 2002-11-13 2004-05-27 Genentech, Inc. Methods and compositions for diagnosing dysplasia
ES2299281B1 (es) * 2003-10-22 2009-04-16 Progenika Biopharma, S.A. Metodos para el diagnostico in vitro y pronostico in vitro del cancer de pancreas, y para el desarrollo de farmacos contra el cancer de pancreas.

Also Published As

Publication number Publication date
EP2054443A2 (de) 2009-05-06
PT2054443E (pt) 2010-10-26
AU2007291077B2 (en) 2012-03-08
WO2008025964A2 (en) 2008-03-06
CA2661803A1 (en) 2008-03-06
US8329875B2 (en) 2012-12-11
ES2351801T3 (es) 2011-02-10
EP2054443B1 (de) 2010-07-21
US20110052586A1 (en) 2011-03-03
GB0616929D0 (en) 2006-10-04
DK2054443T3 (da) 2010-11-15
AU2007291077A1 (en) 2008-03-06
DE602007007958D1 (de) 2010-09-02
WO2008025964A3 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
ATE474857T1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome
ATE509033T1 (de) Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
EA201100231A1 (ru) Диагностический анализ на основе антител
DK1889059T3 (da) Fremgangsmåde til forbedret immunoassay
US20190033316A1 (en) Methods and kits for the diagnosis of cancer
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
NZ599105A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
BRPI0712273A2 (pt) Anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit
JP2016536568A5 (de)
WO2008054724A3 (en) Monoclonal antibodies against osteopontin
DE602007006634D1 (de) Peptidaptamer zum neutralisieren der bindung von platelet-antigen-spezifischen antikörpern und diagnostische und therapeutische anwendungen, die dieses enthalten
MX2013010571A (es) Ensayo de diagnostico de anticuerpo.
Upasani et al. Database on monoclonal antibodies to cytokeratins
JP2012521745A5 (de)
ITRM20040098A1 (it) Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
DE602006020467D1 (de) Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
SE0100595D0 (sv) Immunological detection of prostate diseases and prostatic-related diseases
JP2013513812A5 (de)
UA98632C2 (ru) Антагонистические антитела к notch3 и их применение для профилактики и лечения связанных с notch3 заболеваний
DE602006018458D1 (de) Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
ATE512671T1 (de) Verwendung von antikörpern gegen den lamininrezeptor oder den lamininrezeptorvorläufer zur diagnose von krebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2054443

Country of ref document: EP